SETH LERNER to Adjuvants, Immunologic
This is a "connection" page, showing publications SETH LERNER has written about Adjuvants, Immunologic.
Connection Strength
1.599
-
Bladder cancer: Always consider extravesical sites when BCG fails. Nat Rev Urol. 2014 Jan; 11(1):11-2.
Score: 0.364
-
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31.
Score: 0.230
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
Score: 0.178
-
Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na?ve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):522-524.
Score: 0.126
-
Bacillus Calmette-Gu?rin Manufacturing and SWOG S1602 Intergroup Clinical Trial. J Urol. 2017 03; 197(3 Pt 1):538-540.
Score: 0.112
-
Treatment of high-risk, non-muscle-invasive bladder cancer. Nat Clin Pract Urol. 2006 Aug; 3(8):398-9.
Score: 0.055
-
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol. 2025 Nov; 88(5):430-434.
Score: 0.050
-
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Gu?rin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. Eur Urol Focus. 2025 May; 11(3):448-455.
Score: 0.049
-
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
Score: 0.049
-
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.
Score: 0.048
-
Bladder-sparing Therapy for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec; 86(6):516-527.
Score: 0.048
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
Score: 0.047
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 12 10; 41(35):5437-5447.
Score: 0.045
-
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
Score: 0.040
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.040
-
The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.
Score: 0.037
-
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 06; 3(3):318-340.
Score: 0.035
-
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
Score: 0.027
-
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu?rin. J Urol. 2013 Oct; 190(4):1200-4.
Score: 0.022